Nestlé: closes tender with 84% of Aimmune Therapeutics
(CercleFinance.com) - Nestlé said on Tuesday it has closed its tender offer for a controlling stake in Aimmune Therapeutics and now officially owns approximately 84% of the US food allergy firm.
In a statement, the Swiss food giant said that more than 43.4 million shares have been validly tendered as part of the offer, which expired on Friday 9 October.
In late August, Nestlé said that it had reached an agreement to acquire Aimmune Therapeutics based on a total enterprise value of 2.6 billion dollars.
Aimmune's products help reduce the frequency and severity of allergic reaction to peanuts in children.
The acquisition is expected to be accretive to Nestlé's organic growth in 2021 and accretive to cash earnings by 2022/23.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In a statement, the Swiss food giant said that more than 43.4 million shares have been validly tendered as part of the offer, which expired on Friday 9 October.
In late August, Nestlé said that it had reached an agreement to acquire Aimmune Therapeutics based on a total enterprise value of 2.6 billion dollars.
Aimmune's products help reduce the frequency and severity of allergic reaction to peanuts in children.
The acquisition is expected to be accretive to Nestlé's organic growth in 2021 and accretive to cash earnings by 2022/23.
Copyright (c) 2020 CercleFinance.com. All rights reserved.